6-K - IceCure Medical Ltd.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001213900-26-045896

Filing Date: 2026-04-21

Accepted: 2026-04-21 08:45:12

Documents: 2

Period of Report: 2026-04-21

IceCure Medical Ltd. (Filer) CIK : 0001584371 (see all company filings) EIN. : 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231 Type: 6-K | Act: 34 | File No.: 001-40753 | Film No.: 26876842 SIC : 3841 Surgical & Medical Instruments & Apparatus (CF Office: 08 Industrial Applications and Services)

1 | REPORT OF FOREIGN PRIVATE ISSUER | ea0286976-6k_icecure.htm | 6-K

2 | PRESS RELEASE DATED APRIL 21, 2026 TITLED "ICECURE PARTICIPATES IN SOCIETY OF BR | ea028697601ex99-1.htm | EX-99.1

SECURITIES AND EXCHANGE COMMISSION

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of April 2026

Commission File Number: 001-40753

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

On April 21, 2026, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

This Report of Foreign Private Issuer on Form 6-K (excluding the fourth paragraph of the press release included as Exhibit 99.1 hereto) is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-290046 and 333-258660 ) and Form S-8 (File Nos. 333-270982 , 333-264578 , 333-262620 and 333-281587 ), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.